Phase 1 N=56 Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
Oncology
Primary: Pharmacokinetic (PK) Parameter: AUCtau of ENTO — 1788.9; 7490.0; 4081.5; 3318.0 h*ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=118 Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
Neutropenia
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to 24 Hours Post-dose for POS — 17800; 27300; 25600; 29800 hr*ng/mL
Phase 1 N=11 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects
Lupus Erythematosus, Cutaneous
Primary: Number of Participants With Emergent Chemistry Results by Potential Clinical Importance (PCI) Criteria — 0; 11; 0; 10 Participants
Phase 1 N=141 To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin
Healthy
Primary: AUC0-inf — 42034.90; 40413.44; 43017.95 h*ug/mL
Phase 1 N=45 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
Osteoporosis
Primary: Number of Participants With Adverse Events — 6; 2; 3; 5 Participants
Phase 1 N=140 Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
Metastatic Colorectal Cancer (mCRC)
Primary: Area Under the Concentration-versus-time Curve (AUC) at Cycle 1 (AUC0-336h) of BEVZ92 and Avastin® — 16500000; 16600000 ng.h/mL
Phase 1 N=3 HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
Solid Tumor
Primary: Patients With Elevated Par-4 Levels — 3; 2; 1 Participants
Phase 1 N=26 Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Alcohol Dependence
Primary: Craving for Alcohol in Alcohol Dependence With Citalopram Compared to Placebo — 21; 30.4; 10.8; 10.6 score on a scale
Phase 1 N=58 An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of Eribulin-LF — 1.4; 1.5 mg/m^2
Phase 1 N=5 Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
Neuroblastoma
Primary: Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks — 0; 0; 3 Participants
Phase 1 N=64 Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) — 94.37; 43.84; 106.35; 51.65 ng/mL
Phase 1 N=6 A Study of LY2940680 in Healthy Participants
Healthy Volunteers
Primary: Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 82.7 percentage of dose administered
Phase 1 N=25 A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)
Pulmonary Arterial Hypertension
Primary: Percentage of Participants Who Report 1 or More Adverse Events (AEs)- Healthy Participants — 50.0; 66.7; 50.0; 100.0 Percentage of Participants
Phase 1 N=36 A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
Alzheimer Disease · Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Plasma LY2886721 — 2800; 2580; 10500 nanograms*hours/milliliter (ng*h/mL)
Phase 1 N=42 A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
Alzheimer's Disease
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants